Neupulse Secures £3M for Wearable Neurotherapeutic Device for Tourette Syndrome
Summary
Neupulse has raised £3 million in new funding led by Eos Advisory and the Midlands Engine Investment Fund II through manager Mercia Ventures. The neurotherapeutics company is developing a wrist-worn wearable neuromodulation device to help manage symptoms of Tourette Syndrome, which is believed to affect up to 2% of all children worldwide. Current treatments are limited to medication and behavioral therapy, neither of which are ideal solutions. The funding will accelerate the path to commercial launch in mid-2026.
Why it matters
This funding highlights growing demand for non-invasive, wearable neurotherapeutics that address clear unmet needs in pediatric and adolescent populations. Tourette Syndrome has historically been underserved by medical device innovation, with patients and families often struggling to find effective treatments. Neupulse's wrist-worn device represents a patient-friendly approach that could significantly improve quality of life for young people if clinical validation supports the promising early data. The UK-focused financing also demonstrates regional diversity in neurotech venture funding.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial